Attributable mean 12-month cost per patient or control, stratified by risk factor and age at index date*†
| Variable | No. of participants | Mean cost ± SD, $ | Median cost (IQR), $ | Adjusted mean cost difference between patients and controls, $ (95% CI) | |||
|---|---|---|---|---|---|---|---|
| Patients with RSV | Controls | Patients with RSV | Controls | Patients with RSV | Controls | ||
| All | 14608 | 72040 | 12 080 ± 28 229 | 2410 ± 16 305 | 6760 (5610–9890) | 590 (340–1140) | 9240 (8790–9690) |
| CHD | 719 | 1930 | 40 490 ± 82 500 | 22 730 ± 61 416 | 13 230 (7860–30 730) | 2920 (1100–11 900) | 24 130 (10 780–38 760) |
| Hemodynamically significant CHD | 45 | 67 | 102 540 ± 102 996 | 41 540 ± 56 632 | 68 090 (24 580–139 330) | 19 750 (3000–49 220) | 60 110 (26 700–93 060) |
| Nonhemodynamically significant CHD | 674 | 1863 | 36 350 ± 79 329 | 22 050 ± 61 488 | 12 190 (7550–26 720) | 2800 (1060–10 960) | 17 460 (2960–34 020) |
| CLD | 122 | 427 | 35 420 ± 78 798 | 10 030 ± 32 883 | 11 730 (8510–21 510) | 2600 (1280–6120) | 22 140 (10 420–39 550) |
| Gestational age, wk | |||||||
| 22–28 | 191 | 723 | 31 500 ± 59 582 | 17 570 ± 51 223 | 11 200 (7970–23 590) | 2450 (1070–6380) | 10 860 (880–20 660) |
| 29–32 | 292 | 1339 | 27 220 ± 51 452 | 9790 ± 25 503 | 9710 (6520–19 670) | 1640 (790–5170) | 16 510 (10 070–24 290) |
| 33–35 | 909 | 4421 | 16 050 ± 42 434 | 4430 ± 26 465 | 7710 (5910–12 350) | 810 (400–1920) | 11 220 (8730–14 550) |
| 36–43 | 13216 | 65557 | 11 190 ± 24 682 | 1950 ± 14 093 | 6640 (5580–9500) | 540 (320–1010) | 8920 (8500–9360) |
| Premature | 1392 | 6483 | 20 510 ± 50 022 | 7000 ± 30 375 | 8430 (6160–14 510) | 1070 (500–2950) | 12 280 (9450–15 230) |
| No comorbidities and full-term birth | 10 200 ± 20 273 | 1590 ± 11 301 | 6570 (5550–9210) | 560 (330–1030) | 8170 (7830–8500) | ||
| Age at index hospitalization, mo | |||||||
| < 2 | 4566 | 19500 | 13 670 ± 32 168 | 3550 ± 19 049 | 7160 (5860–11 390) | 680 (400–1320) | 10 710 (9880–11 530) |
| 2–3 | 3068 | 14525 | 10 350 ± 24 692 | 2390 ± 20 908 | 6380 (5530–8910) | 590 (350–1120) | 7780 (6840–8770) |
| 4–5 | 1752 | 10209 | 11 240 ± 23 570 | 2100 ± 14 845 | 6530 (5520–9410) | 570 (330–1110) | 8270 (6980–9460) |
| 6–11 | 2616 | 12531 | 11 770 ± 25 438 | 1890 ± 12 996 | 6820 (5650–9780) | 590 (330–1130) | 9070 (8160–10 020) |
| 12–23 | 2606 | 15275 | 12 200 ± 30 100 | 1610 ± 9306 | 6660 (5390–9480) | 490 (260–990) | 8690 (7460–9910) |
Note: CHD = congenital heart disease, CI = confidence interval, CLD = congenital lung disease, IQR = interquartile range, RSV = respiratory syncytial virus, SD = standard deviation.
↵* Cost adjusted to 2020 Canadian dollars, rounded to the nearest tens digit, and adjusted for covariates using the propensity score.
↵† Index dates for patients were admission dates for their first RSV hospitalization. Index dates for controls were randomly generated based on the distribution of index dates among patients with RSV.